Saliva-based POC Diagnostic Platform
Infectious Disease (e.g., COVID-19) and Cancer Screening
Pre-clinicalActive
Key Facts
Indication
Infectious Disease (e.g., COVID-19) and Cancer Screening
Phase
Pre-clinical
Status
Active
Company
About FlexBioTech
Founded in 2020 and headquartered in Boston, FlexBioTech is a private, pre-revenue diagnostics company targeting the point-of-care testing market. The company is developing a proprietary platform centered on saliva-based collection and a portable reader, aiming to diagnose diseases like COVID-19 and cancers with high accuracy at a low cost. Its mission is to shift healthcare from a reactive, hospital-centered model to a preventative, person-centered one, particularly in resource-limited settings. While promising, the company faces significant risks including platform development, clinical validation, and intense competition in the rapidly evolving diagnostics landscape.
View full company profile